1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

FDA Duchenne Drug Review Smacks Sarepta

 
• By Donna Young

FDA drug reviewers raised considerable doubts about whether Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug eteplirsen, which it wants to market as Exondys under an accelerated approval, was effective in treating the disease – calling into question whether the investigational medicine actually increased the levels of dystrophin, a protein essential for normal muscular structure and function and the lack of which is at the heart of the condition.

FDA drug reviewers raised considerable doubts about whether Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug eteplirsen, which it wants to market as Exondys under an accelerated approval, was effective in treating the disease – calling into question whether the investigational medicine actually increased the levels of dystrophin, a protein essential for normal muscular structure and function and the lack of which is at the heart of the condition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.